Velcade for multiple myeloma approved in India
EPP News Bureau – Mumbai
The Indian regulatory authorities have given permission for import of Velcade (bortezomib), a new line of treatment for multiple myeloma, a devastating cancer of the blood, bringing new hope to those suffering from the disease. It is expected to be available here as soon as regulatory formalities are completed, according to a press release.
Multiple myeloma is a devastating cancer of the blood that is under-recognised and has no cure. It is the second most prevalent blood cancer after non-Hodgkin’s lymphoma. Although multiple myeloma represents only one per cent of all cancers, it represents two per cent of all cancer deaths. Most patients with multiple myeloma survive on an average for just three years. Only 30 per cent survive longer than five years. It has one of the lowest long-term survival rates (20 years) of all cancers.
The World Health Organisation (WHO) research states that 73,943 people worldwide developed multiple myeloma in 2000. “As physicians, we look forward to new therapies that will benefit patients. When multiple myeloma patients fail two previous line of treatment, their cancer is one of the most difficult to treat’’ says Dr M.B. Agarwal, haemo-oncologist with Bombay Hospital, Lilavati Hospital and Breach Candy Hospital. “But with VELCADE, we are able to give them another option which, in many cases, can give them another chance at life.“